112 related articles for article (PubMed ID: 32821347)
1. Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5.
Al-Jameel W; Gou X; Forootan SS; Fayi MSA; Rudland PS; Forootan FS; Zhang J; Cornford PA; Hussain SA; Ke Y
Oncotarget; 2020 Aug; 11(31):3025. PubMed ID: 32821347
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5.
Al-Jameel W; Gou X; Forootan SS; Al Fayi MS; Rudland PS; Forootan FS; Zhang J; Cornford PA; Hussain SA; Ke Y
Oncotarget; 2017 May; 8(19):31041-31056. PubMed ID: 28415688
[TBL] [Abstract][Full Text] [Related]
3. Correction: A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer.
Jo JK; Oh JJ; Kim YT; Moon HS; Choi HY; Park S; Ho JN; Yoon S; Park HY; Byun SS
Oncotarget; 2018 Aug; 9(61):31938. PubMed ID: 30159135
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
5. Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3.
Ding H; Sun Y; Hou Y; Li L
Urol Oncol; 2014 Jul; 32(5):720-6. PubMed ID: 24837011
[TBL] [Abstract][Full Text] [Related]
6. Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment.
Ziouziou H; Andrieu C; Laurini E; Karaki S; Fermeglia M; Oueslati R; Taieb D; Camplo M; Siri O; Pricl S; Katsogiannou M; Rocchi P
Oncotarget; 2018 Jun; 9(47):28797. PubMed ID: 29983898
[TBL] [Abstract][Full Text] [Related]
7. Correction: Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.
De Beule N; Menu E; Bertrand MJM; Favreau M; De Bruyne E; Maes K; De Veirman K; Radwanska M; Samali A; Magez S; Vanderkerken K; De Trez C
Oncotarget; 2018 Apr; 9(32):22871. PubMed ID: 29854322
[TBL] [Abstract][Full Text] [Related]
8. Correction: LncRNA-SVUGP2 suppresses progression of hepatocellular carcinoma.
Hu J; Song C; Duan B; Zhang X; Li D; Zhu L; Gao H
Oncotarget; 2018 Jul; 9(58):31311. PubMed ID: 30131857
[TBL] [Abstract][Full Text] [Related]
9. Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget.
Qiu YQ; Yang CW; Lee YZ; Yang RB; Lee CH; Hsu HY; Chang CC; Lee SJ
Oncotarget; 2019 Aug; 10(47):4919. PubMed ID: 31448057
[TBL] [Abstract][Full Text] [Related]
10. Correction: Genipin suppresses colorectal cancer cells by inhibiting the Sonic Hedgehog pathway.
Kim BR; Jeong YA; Na YJ; Park SH; Jo MJ; Kim JL; Jeong S; Lee SY; Kim HJ; Oh SC; Lee DH
Oncotarget; 2018 Jun; 9(47):28796. PubMed ID: 29983897
[TBL] [Abstract][Full Text] [Related]
11. Correction: Oncogenic extracellular HSP70 disrupts the gap-junctional coupling between capillary cells.
Thuringer D; Berthenet K; Cronier L; Jego G; Solary E; Garrido C
Oncotarget; 2021 Jul; 12(15):1564-1565. PubMed ID: 34316335
[TBL] [Abstract][Full Text] [Related]
12. Correction: Colon cancer-induced interleukin-35 inhibits betacatenin- mediated pro-oncogenic activity.
Jiang Y; Ma Y; Li R; Sun J
Oncotarget; 2018 Aug; 9(60):31788. PubMed ID: 30167095
[TBL] [Abstract][Full Text] [Related]
13. Correction: Mitochondrial clearance by the STK38 kinase supports oncogenic Ras-induced cell transformation.
Bettoun A; Joffre C; Zago G; Surdez D; Vallerand D; Gundogdu R; Sharif AAD; Gomez M; Cascone I; Meunier B; White MA; Codogno P; Parrini MC; Camonis JH; Hergovich A
Oncotarget; 2018 Apr; 9(32):22870. PubMed ID: 29854321
[TBL] [Abstract][Full Text] [Related]
14. Correction: A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy.
Hsu TI; Chen YJ; Hung CY; Wang YC; Lin SJ; Su WC; Lai MD; Kim SY; Wang Q; Qian K; Goto M; Zhao Y; Kashiwada Y; Lee KH; Chang WC; Hung JJ
Oncotarget; 2019 Nov; 10(60):6536-6537. PubMed ID: 31741716
[TBL] [Abstract][Full Text] [Related]
15. Correction: NLRP6 targeting suppresses gastric tumorigenesis via P14
Wang H; Xu G; Huang Z; Li W; Cai H; Zhang Y; Xiong D; Liu G; Wang S; Xue Z; Luo Q
Oncotarget; 2018 Oct; 9(84):35512. PubMed ID: 30464807
[TBL] [Abstract][Full Text] [Related]
16. Correction: Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer
Chang I; Mitsui Y; Kim SK; Sun JS; Jeon HS; Kang JY; Kang NJ; Fukuhara S; Gill A; Shahryari V; Tabatabai ZL; Greene KL; Dahiya R; Shin DM; Tanaka Y
Oncotarget; 2018 Sep; 9(75):34190. PubMed ID: 30344932
[TBL] [Abstract][Full Text] [Related]
17. Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
Jung DB; Yun M; Kim EO; Kim J; Kim B; Jung JH; Wang E; Mukopadhyay D; Hammond E; Dredge K; Shridhar V; Kim SH
Oncotarget; 2019 Sep; 10(54):5669. PubMed ID: 31608142
[TBL] [Abstract][Full Text] [Related]
18. Correction: HOTAIR regulates HK2 expression by binding endogenous miR-125 and miR-143 in oesophageal squamous cell carcinoma progression.
Ma J; Fan Y; Feng T; Chen F; Xu Z; Li S; Lin Q; He X; Shi W; Liu Y; Liu Z; Zhu B; Cao X
Oncotarget; 2019 Mar; 10(21):2112. PubMed ID: 31007852
[TBL] [Abstract][Full Text] [Related]
19. Correction: HOTAIR regulates HK2 expression by binding endogenous miR-125 and miR-143 in oesophageal squamous cell carcinoma progression.
Ma J; Fan Y; Feng T; Chen F; Xu Z; Li S; Lin Q; He X; Shi W; Liu Y; Liu Z; Zhu B; Cao X
Oncotarget; 2018 May; 9(34):23843. PubMed ID: 29809195
[TBL] [Abstract][Full Text] [Related]
20. Correction: Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates heptotoxicity via phase I and II drug metabolizing enzymes.
Hakkim FL; Bakshi HA; Khan S; Nasef MM; Farzand R; Sam S; Rashan L; Al-Baloshi MS; Abdo Hasson SSA; Jabri AA; McCarron PA; Tambuwala MM
Oncotarget; 2020 Jun; 11(23):2259-2261. PubMed ID: 32577169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
